ADAM17 and Sepsis: The use of active-site ADAM10 inhibitors such as GI254023X has shown promising preclinical results to improve sepsis (10, 19); however, the evaluation of these agents in humans remains limited by nonspecific inhibitory effects on ADAM17 and unfavorable toxicities with chronic use (84, 85).